Humacyte, Inc. (HUMA) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers Humacyte, Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2026. Humacyte is a commercial-stage biotechnology company developing bioengineered human tissues. Its primary commercial product is Symvess, an acellular tissue engineered vessel (ATEV) approved by the FDA for vascular trauma. The company is also advancing clinical trials for Symvess in AV access for hemodialysis and developing a pipeline for other indications including PAD, CABG, and Type 1 diabetes (BioVascular Pancreas).
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $901 |
| Net Loss | $(54,421) |
| Operating Loss | $(55,931) |
| Cash and Cash Equivalents (as of June 30, 2026) | $79,903 |
| Working Capital | $77,839 |
| Long-Term Debt (Carrying Value) | $36,324 |
| Accumulated Deficit | $(781,269) |
Note: Revenue is primarily derived from Symvess product sales ($899k) and minimal contract revenue ($2k). Cost of Goods Sold was $3.3 million, heavily impacted by a $2.3 million inventory reserve.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10% year-over-year (from $818k to $901k), driven by a 264% increase in product revenue ($247k to $899k) as commercial sales of Symvess expanded. Contract revenue declined significantly as prior-year research contracts concluded.
- Operating Expenses: Total operating expenses increased 6% to $56.8 million. Research and Development (R&D) expenses remained flat at $37.6 million, while Cost of Goods Sold surged 808% due to inventory write-downs and commercialization costs.
- Net Loss Volatility: The company reported a net loss of $54.4 million, compared to a net income of $1.5 million in the prior year. This shift is primarily due to the absence of a $44.3 million non-cash gain from the fair value remeasurement of the Contingent Earnout Liability recorded in the prior period.
- Liquidity Position: Cash and cash equivalents increased from $50.5 million at year-end 2025 to $79.9 million, bolstered by significant equity financing activities in the first half of 2026.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. The company states it will not have sufficient liquidity to fund operations beyond one year without generating sufficient commercial cash flows or obtaining additional capital.
- Capital Raising: The company raised approximately $72.1 million in net proceeds during the six months ended June 30, 2026, via a Public Offering ($53.8 million), a Registered Direct Offering ($18.3 million), and ATM sales ($4.6 million).
- Cost Reductions: In May 2026, Humacyte implemented a workforce reduction of approximately 45 employees, with estimated one-time charges of $0.8 million and projected net annual savings of $14.3 million.
- Nasdaq Delisting Risk: On July 31, 2026, the company received a notice from Nasdaq regarding failure to maintain the minimum $1.00 bid price requirement. The company has 180 days to regain compliance.
- Legal Proceedings: The company is defending a securities class action lawsuit regarding alleged misrepresentations about Symvess safety and manufacturing. Discovery commenced in June 2026. The company cannot estimate potential losses.
- Inventory Reserves: A significant unusual item was the $2.3 million inventory reserve recorded in Cost of Goods Sold to adjust inventory to net realizable value based on demand forecasts.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and the one-year liquidity horizon.
- Symvess Commercialization: Assess the trajectory of Symvess sales volume and reimbursement rates to determine if organic revenue can cover operating costs.
- Inventory Valuation: Review the assumptions behind the $11.2 million inventory allowance and the risk of further write-downs if demand does not materialize.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 threshold within the 180-day compliance window to avoid delisting.
- Legal Exposure: Track the progress of the securities class action lawsuit and any potential settlement impacts.
- Debt Covenants: Review the terms of the $40 million Term Loan Facility (11.5% interest) and ensure compliance with liquidity and revenue covenants required for future tranches.